LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.8030
-0.0546 (-6.37%)
As of 10:31AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.8576
Open0.9400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.8030 - 0.9400
52 Week Range0.6000 - 2.2400
Volume12,083
Avg. Volume72,855
Market Cap63.146M
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.35
Trade prices are not sourced from all markets
  • More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media
    Newsfile

    More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media

    Seattle, Washington--(Newsfile Corp. - August 15, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology.When you've got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of ...

  • ACCESSWIRE

    Lexaria Bioscience Announces it has Received Four New Patents

    KELOWNA, BC / ACCESSWIRE / August 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted.

  • ACCESSWIRE

    Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

    KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated. Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing.

  • ACCESSWIRE

    Lexaria Bioscience Receives Cannabis R&D License from Health Canada

    KELOWNA, BC / ACCESSWIRE / August 13, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed. Lexaria’s new cannabis R&D license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.

  • ACCESSWIRE

    Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

    KELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, announces the successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECHTM technology. A primary goal of the R&D Program was to determine whether Lexaria’s DehydraTECH technology causes the formation of a new molecular entity (“NME”) through its processing.

  • ACCESSWIRE

    Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

    KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines. Integra partners with select underexposed and undervalued emerging growth company and leverages decades of market experience with a robust proprietary database to continuously maximize market visibility throughout their clients’ different development cycles. Integra is being engaged for an initial six-month contract and will receive US$12,500 per month and a total of 150,000 restricted common shares of the Company.

  • ACCESSWIRE

    Lexaria Bioscience Summarizes its Eleven Technology Licenses

    KELOWNA, BC / ACCESSWIRE / July 30, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” said Chris Bunka, Chief Executive Officer. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous.

  • Hill Street Beverage Co. and Lexaria Bioscience Enter Global Manufacturing & Licensing Partnership
    CNW Group

    Hill Street Beverage Co. and Lexaria Bioscience Enter Global Manufacturing & Licensing Partnership

    Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide. "Hill Street") and Lexaria Bioscience Corp. (LXRP) (CSE:LXX), an innovator in drug delivery platforms, today announced a multi-faceted expansion of their relationship . Hill Street and Lexaria have entered into a Joint Manufacturing Partnership ("JMP") valid for 10 years to produce DehydraTECH™ commercial products under a new brand to be announced, including both processed THC and CBD powders in the form of compressed tablets, capsules, or sachets for new consumer products for sale in Canada and for export where permitted, subject to Health Canada approval.

  • ACCESSWIRE

    Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership

    Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide. Manufacturing will be done at Hill Street’s soon to be acquired OneLeaf Cannabis cultivation and processing facility in Regina, Saskatchewan, pending licensing by Health Canada.

  • CNW Group

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • ACCESSWIRE

    Lexaria Bioscience Enters CBD License Agreement with Universal Hemp

    KELOWNA, BC / ACCESSWIRE / July 11, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp., to provide Lexaria’s patented DehydraTECHTM technology to Universal Hemp LLC, a B2B manufacturing company of high-performing hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries, for utilization into many CBD-based food ingredients to be produced and sold across the USA immediately, and in Canada when regulations permit. Competitive financial details including royalty rates remain confidential and undisclosed although the companies have agreed to disclose minimum payments over the life of the agreement of US$3,750,000.

  • ACCESSWIRE

    Lexaria Bioscience Enters CBD Beverage License Agreement with Nic’s Beverages

    KELOWNA, BC / ACCESSWIRE / July 10, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria’s patented DehydraTECHTM technology to Nic’s Beverages L.L.C. for use in CBD-based beverages to be produced and sold throughout the United States.

  • PR Newswire

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • ACCESSWIRE

    Lexaria Announces 2019 Annual and Special Meeting Results

    KELOWNA, BC / ACCESSWIRE / June 21, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2019 Annual and Special Meeting ...

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

    NEW YORK, June 13, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled,.

  • Newsfile

    DehydraTECH: The Cynosure of Efficient CBD Delivery -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 13, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).Scientists use words like "bioavailability," "pharmacokinetics" and "targeted" in describing keys to efficiently treating disease and conditions. To the patient, it is just swallowing a pill, but there are years of research that goes ...

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements

    NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • ACCESSWIRE

    Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents

    New Enhanced DehydraTECH™ Formulation Delivers 8X More CBD into Blood and Over 19X More CBD into Brain Tissue than Standard Industry Formulations. KELOWNA, BC / ACCESSWIRE / June 4, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECH™ delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. The Company has filed new patent applications related to the recent innovations.

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

    Consider what [Lexaria BioScience Corp.’s DehydraTECH] technology could mean for the CBD edibles space. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology.

  • GlobeNewswire

    Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Discussing Disruptive Potential of CBD Delivery Technology

    NEW YORK, May 30, 2019 -- via CannabisNewsWire – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire.

  • ACCESSWIRE

    Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

    KELOWNA, BC / ACCESSWIRE / May 28, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria's DehydraTECHTM delivery technology with generic nanotech techniques delivers 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. On March 20, 2019, Lexaria announced it was beginning a series of animal studies with multiple objectives that included developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier ("BBB") to enter brain tissue.

  • ACCESSWIRE

    Lexaria Bioscience and Nuka Enterprises' 1906 Expand Cannabis Product Relationship

    KELOWNA, BC / ACCESSWIRE / May 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), an innovator in drug delivery platforms, today announced the most reliable fast acting edibles on the market will now be available across the country through a major expansion in operations by Nuka Enterprises LLC, ("Nuka") maker of 1906 cannabis edibles for high functioning adults. Last year, Nuka acquired contractual options to expand its use of DehydraTECHTM technology. Exercising some of those options, Nuka plans to expand operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020.

  • ACCESSWIRE

    Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

    Lexaria's DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles. KELOWNA, BC / ACCESSWIRE / May 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil.